Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT00024323 · ClinicalTrials.gov registry record · Phase 1

Combination Chemotherapy in Treating Patients With Advanced Cancer

A Phase 1 study, sponsored by Vion Pharmaceuticals.

Completed
Registry status
Phase 1
Development phase

NCT00024323: Completed Phase 1 study, sponsored by Vion Pharmaceuticals.

NCT00024323 is a Phase 1 study that has completed, run by Vion Pharmaceuticals. According to ClinicalTrials.gov, the official US trial registry.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT00024323, a Phase 1 study, has completed, sponsored by Vion Pharmaceuticals.

COMPLETED
Registry status
Phase 1
Development phase

Study Summary

RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. Combining more than one drug may kill more tumor cells. PURPOSE: Phase I trial to study the effectiveness of combining 3-AP with cisplatin in treating patients who have advanced cancer.

Interventions

  • DRUG cisplatin
  • DRUG triapine

Trial Details

FieldValue
Start Date 2001-03
Est. Completion 2003-06
Phase Phase 1
Vion Pharmaceuticals

19 total trials

What the finished NCT00024323 record still lists

NCT00024323 is an interventional study that assigns participants to a tested intervention. An enrollment target was not published in the registry record, which is common for early-stage or observational entries.

The record links to 0 conditions, and to 2 interventions - of which cisplatin is the first listed.

NCT00024323 does not publish any study locations in the registry export this page uses.

Frequently Asked Questions

What is clinical trial NCT00024323 about?

NCT00024323 is a clinical study titled "Combination Chemotherapy in Treating Patients With Advanced Cancer". RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. Combining more than one drug may kill more tumor cells. PURPOSE: Phase I trial to study the effectiveness of combining 3-AP with cisplatin in treating patients who have advanced c...

What is the current status of trial NCT00024323?

This trial is currently completed. It is a Phase 1 study. The study started on 2001-03. Estimated completion is 2003-06.

What interventions are being tested in trial NCT00024323?

The interventions under investigation include: cisplatin (DRUG), triapine (DRUG).

Who is sponsoring clinical trial NCT00024323?

This trial is sponsored by Vion Pharmaceuticals, which has 19 total clinical trials registered on ClinicalTrials.gov.

Nationwide trials with similar profiles

Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.

Similar registry start date

  • NCT05988463 · started 2027-01-01 · Phase 1

    Dose-Escalation Study of Artesunate Patients With IPF

  • NCT07219706 · started 2026-12-10 · NA

    Dietary Fiber and Time Restricted Eating

  • NCT02831335 · started 2026-12-01

    Technical Development of Multi-Parametric Renocerebral MRI

  • NCT05962346 · started 2026-12 · NA

    Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia

Source: ClinicalTrials.gov NCT00024323, the US trial registry maintained by the National Library of Medicine. NCT00024323 (unsized enrollment · none site footprint · completed) retrieved and formatted by PlainTrial, see methodology.